Results 121 to 130 of about 2,011 (173)
Australian prescriberSome of the next articles are maybe not open access.
Related searches:
Related searches:
Nervenheilkunde, 2020
Abstract Objective Cariprazine is a new antipsychotic drug approved for the treatment of schizophrenia in Europe in 2017. Clinical studies suggest advantages of cariprazine in comparison to other antipsychotic agents regarding therapeutic effects on “negative symptoms”, antipsychotic-induced weight gain and increased serum prolactin levels ...
Maximilian Gahr, Simon Riedesser
openaire +1 more source
Abstract Objective Cariprazine is a new antipsychotic drug approved for the treatment of schizophrenia in Europe in 2017. Clinical studies suggest advantages of cariprazine in comparison to other antipsychotic agents regarding therapeutic effects on “negative symptoms”, antipsychotic-induced weight gain and increased serum prolactin levels ...
Maximilian Gahr, Simon Riedesser
openaire +1 more source
pharma-kritik, 2019
Ein neues Neuroleptikum, das ungefähr dieselben Wirkungen hat wie Aripiprazol, aber durch eine sehr lange Halbwertszeit auffällt.
openaire +1 more source
Ein neues Neuroleptikum, das ungefähr dieselben Wirkungen hat wie Aripiprazol, aber durch eine sehr lange Halbwertszeit auffällt.
openaire +1 more source
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Brexpiprazole, cariprazine hydrochloride, and flibanserin
Journal of the American Pharmacists Association, 2016Brexpiprazole (RexultidOtsuka) is an atypical antipsychotic agent with properties and uses that are most similar to those of aripiprazole (e.g., Abilify). It is indicated for the treatment of patients with schizophrenia, and for adjunctive treatment in patients with major depressive disorder (MDD).
Daniel A, Hussar, Rebecca, Shatynski
openaire +2 more sources
Cariprazine: A Review in Schizophrenia
CNS Drugs, 2017Cariprazine (Vraylar™) is a dopamine D3-preferring D2/D3 receptor partial agonist indicated for the treatment of patients with schizophrenia. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of cariprazine in patients with this disorder.
openaire +2 more sources